drugset / Trial / NCT05176951
A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of treprostinil palmitil inhalation powder (TPIP) compared with placebo
Timeline
- Start
- 2022-12-22
- Primary completion
- 2024-03-14
- Completion
- 2024-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Treprostinil Palmitil | Small molecule | 80 ug | Inhaled |
| Subject | Treprostinil Palmitil | Small molecule | 640 ug | Inhaled |